BioMarin Pharmaceutical Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $91.56. The average 1-year stock price forecast is 63.65% higher than the current stock price, while the lowest is $60 (+7.24%) and the highest is $122 (+118.05%).

Price Target: $91.56 (+63.65%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$60	$91.56	$90	$122
Change	+7.24%	+63.65%	+60.86%	+118.05%

Analyst Ratings

The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	14	14	13	14	14	16
Buy	6	6	6	6	6	5
Hold	6	6	6	7	7	7
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	26	26	25	27	27	28

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Laaman Morgan Stanley	Morgan Stanley	Buy Reiterates $124 → $122	Buy	Reiterates	$124 → $122	+118.05%	Oct 21, 2026
Allison Bratzel Piper Sandler	Piper Sandler	Buy Maintains $90	Buy	Maintains	$90	+60.86%	Oct 21, 2026
Phil Nadeau TD Cowen	TD Cowen	Buy Maintains $120	Buy	Maintains	$120	+114.48%	Oct 21, 2026
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $86	Buy	Maintains	$86	+53.71%	Oct 20, 2026
Jessica Fye J.P. Morgan	J.P. Morgan	Buy Reiterates $86 → $87	Buy	Reiterates	$86 → $87	+55.50%	Oct 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.92B

from 3.22B

21.77%

from 3.22B

Revenue Next Year

4.50B

from 3.92B

14.83%

from 3.92B

EPS This Year

3.51

from 3.15

11.38%

from 3.15

EPS Next Year

6.39

from 3.51

82.24%

from 3.51

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.85B	2.10B	2.42B	2.85B	3.22B	3.92B
Revenue Growth	-0.76%	13.53%	15.42%	17.97%	12.87%	21.77%
Operating Income	-74.32M	54.68M	185.77M	474.21M	650.73M	640.33M
Net Income	-64.08M	141.56M	167.65M	426.86M	348.90M	327.15M
EPS	-	-	-	-	3.15	3.51
EPS Growth	-	-	-	-	-10.51%	11.38%
Forward PE	85.79	39.00	38.98	17.86	12.37	15.95
Free Cash Flow	-	-	-	-	724.96M	588.50M
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	4.0B
Avg	3.9B
Low	3.9B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	25.3%
Avg	21.8%
Low	20.0%

EPS Forecast

Chart

EPS	2026	2027	2028
High	3.79
Avg	3.51
Low	3.37

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	20.3%
Avg	11.4%
Low	7.0%